Could a molecule from a rainforest tree treat solid tumour cancers?
Scientists at The Institute of Cancer Research, London, are collaborating with life sciences company QBiotics to understand the molecular and cellular mechanisms of a potential new cancer drug.
The collaborative team will study the effects of tigilanol tiglate – a naturally occurring small molecule derived from the seeds of the blushwood tree, Fontainea picrosperma, which grows in the rainforests of northeastern Australia.
They are investigating its effects in samples from patients with head and neck cancer taking part in a clinical trial.
Injected directly into tumours, this potential new drug is currently under development as a treatment for a range of solid tumours, including head and neck cancer and soft tissue sarcoma.
The blushwood tree has long been of interest to QBiotics’ scientists after they observed that animals that feed on its fruit find the seeds highly unpalatable.
QBiotics’ chemists subsequently isolated a compound with anti-cancer properties from the seed – tiglanol tiglate – which may also be responsible for its unpalatability and developed a method for semi-synthesising it in the laboratory.
Tigilanol tiglate is already registered in the UK, Europe, the USA and Australia for use as a cancer treatment for dogs.
Studies by QBiotics show that tigilanol tiglate has a multifactorial mode of action, directly destroying treated tumour cells, disrupting the tumour blood supply, triggering a localised immune response and potentially leading to a systemic immune response in some patients. However, the drugs precise mechanism of action remains unclear.
Phase II trial of tigilanol tiglate
A Phase II clinical trial, led by QBiotics, is currently underway to assess the effectiveness of tigilanol tiglate for the treatment of patients with advanced head and neck cancer.
In addition to its potential as a monotherapy, preclinical studies suggest that tigilanol tiglate could enhance the effectiveness of other cancer treatments, including immunotherapy, chemotherapy and radiotherapy.
The researchers say that gaining a better understanding of the drug’s mechanism of action could lead to the development of combination strategies that are even more powerful at destroying solid tumours.
Dr Steven Ogbourne, Chief Translational Research Officer at QBiotics, said: “This collaboration represents an important aspect of exploring tigilanol tiglate’s potential as a cancer treatment. By leveraging the ICR’s cutting-edge technology and world-class expertise in translational research, we hope to deepen our understanding of the precise mechanism of action of this promising drug candidate.
“Ultimately, the findings could help us navigate towards the most effective way of using this tigilanol tiglate to deliver significant benefits for patients with a range of solid tumours.”
Diana Spencer, Senior Digital Content Editor, DDW
